Currently, the US Food and Drug Administration has approved the use of some therapeutic agents utilizing this strategy, such as vascular endothelial growth factor (VEGF)‐specific antibody bevacizumab (Avastin; Roche/Genentech), sorafenib (Nexavar; Bayer), sunitinib (Sutent; Pfizer), pazopanib (Votrient; GlaxoSmithKline), and vandetanib (Zactima; AstraZeneca).[15] Although promising, clinical research demonstrated that antiangiogenic therapy exhibits short or slight therapy outcomes, and cancer recurrence. Here, VEGFA is linked to cancer.